Rescue of a human mRNA splicing defect by the plant cytokinin kinetin

Human Molecular Genetics

Volumn 13, Issue 4, 2004, Pages 429-436

  Slaugenhaupt, Susan A ^a,b,d   Mull, James ^a,b   Leyne, Maire ^a,b   Cuajungco, Math P ^a,b   Gill, Sandra P ^a,b   Hims, Matthew M ^a,b   Quintero, Fabiola ^a,b   Axelrod, Felicia B ^c   Gusella, James F ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N BENZYLADENINE; CYTOKININ; I KAPPA B KINASE; I KAPPA B KINASE COMPLEX ASSOCIATED PROTEIN; KINETIN; MESSENGER RNA; MESSENGER RNA PRECURSOR; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CONTROLLED STUDY; DYSAUTONOMIA; EXON; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN CELL; INTRON; NERVOUS SYSTEM; NONHUMAN; PATHOGENESIS; PENETRANCE; PRIORITY JOURNAL; RNA SPLICING; TISSUE SPECIFICITY;

ADENINE; ALTERNATIVE SPLICING; CARRIER PROTEINS; CELLS, CULTURED; CYTOKININS; DYSAUTONOMIA, FAMILIAL; EXONS; HUMANS; KINETIN; MYOSIN HEAVY CHAINS; MYOSIN TYPE V; RNA PRECURSORS; RNA, MESSENGER;

EID: 1242353105     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddh046     Document Type: Article

References (37)

1. Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W. et al. (2001) Initial sequencing and analysis of the human genome. Nature, 409, 860-921.
2. Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A. et al. (2001) The sequence of the human genome. Science, 291, 1304-1351.
3. Nissim-Rafinia, M. and Kerem, B. (2002) Splicing regulation as a potential genetic modifier. Trends Genet., 18, 123-127.
4. Will, C.L. and Luhrmann, R. (2001) Spliceosomal UsnRNP biogenesis, structure and function. Curr. Opin. Cell Biol., 13, 290-301.
5. Reed, R. (2000) Mechanisms of fidelity in pre-mRNA splicing. Curr. Opin. Cell Biol., 12, 340-345.
6. Graveley, B.R. (2000) Sorting out the complexity of SR protein functions. RNA, 6, 1197-1211.
7. Jiang, Z.H., Zhang, W.J., Rao, Y. and Wu, J.Y. (1998) Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc. Natl Acad. Sci. USA, 95, 9155-9160.
8. Mayeda, A., Helfman, D.M. and Krainer, A.R. (1993) Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF. Mol. Cell. Biol., 13, 2993-3001.
9. Nissim-Rafinia, M., Chiba-Falek, O., Sharon, G., Boss, A. and Kerem, B. (2000) Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum. Mol. Genet., 9, 1771-1778.
10. Hofmann, Y., Lorson, C.L., Stamm, S., Androphy, E.J. and Wirth, B. (2000) Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc. Natl Acad. Sci. USA, 97, 9618-9623.
11. Chang, J.G., Hsieh-Li, H.M., Jong, Y.J., Wang, N.M., Tsai, C.H. and Li, H. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl Acad. Sci. USA, 98, 9808-9813.
12. Andreassi, C., Jarecki, J., Zhou, J., Coovert, D.D., Monani, U.R., Chen, X., Whitney, M., Pollok, B., Zhang, M., Androphy, E. et al. (2001) Aclarubicin treatment restores SMN levels to cells derived from type 1 spinal muscular atrophy patients. Hum. Mol. Genet., 10, 2841-2849.
13. Zhang, M.L., Lorson, C.L., Androphy, E.J. and Zhou, J. (2001) An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther., 8, 1532-1538.
14. Sumner, C.J., Huynh, T.N., Markowitz, J.A., Perhac, J.S., Hill, B., Coovert, D.D., Schussler, K., Chen, X., Jarecki, J., Burghes, A.H. et al. (2003) Valproic acid increases SNM levels in spinal muscular atrophy patient cells. Ann. Neurol., 54, 647-654.
15. Brichta, L., Hofmann, Y., Hahnen, E., Siebzehnrubl, F.A., Raschke, H., Blumcke, I., Eyupoglu, I.Y. and Wirth, B. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet., 12, 2481-2489.
16. Maayan, C., Kaplan, E., Shachar, S., Peleg, O. and Godfrey, S. (1987) Incidence of familial dysautonomia in Israel 1977-1981. Clin. Genet., 32, 106-108.
17. Axelrod, F.B. (1995) Familial Dysautonomia. In Robertson, D. and Biaggioni, I. (eds), Disorders of the Autonomic Nervous System. Harwood Academic, Luxembourg, pp. 217-231.
18. Anderson, S.L., Coli, R., Daly, I.W, Kichula, E.A., Rork, M.J., Volpi, S.A., Ekstein, J. and Rubin, B.Y. (2001) Familial dysautonomia is caused by mutations of the IKAP gene. Am. J. Hum. Genet., 68, 753-758.
19. Leyne, M., Mull, J., Gill, S.P., Cuajungco, M.P., Oddoux, C., Blumenfeld, A., Maayan, C., Gusella, J.F., Axelrod, F.B., Slaugenhaupt, S.A. (2003) Identification of the first non-Jewish mutation in Familial Dysautonomia. Am. J. Med. Genet., 118A, 305-308.
20. Slaugenhaupt, S.A., Blumenfeld, A., Gill, S.P, Leyne, M., Mull, J., Cuajungco, M.P., Liebert, C.B., Chadwick, B., Idelson, M., Reznik, L. et al. (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am. J. Hum. Genet., 68, 598-605.
21. Hawkes, N.A., Otero, G., Winkler, G.S., Marshall, N., Dahmus, M.E., Krappmann, D., Scheidereit, C., Thomas, C.L., Schiavo, G., Erdjument-Bromage, H. et al. (2002) Purification and characterization of the human elongator complex. J. Biol. Chem., 277, 3047-3052.
22. Holmberg, C., Katz, S., Lerdrup, M., Herdegen, T., Jaattela, M., Aronheim, A. and Kallunki, T. (2002) A novel specific role for I-kappa B kinase complex-associated protein in cytosolic stress signaling. J. Biol. Chem., 277, 31918-31928.
23. Cuajungco, M.P., Leyne, M., Mull, J., Gill, S.P., Lu, W., Zagzag, D., Axelrod, F.B., Maayan, C., Gusella, J.F. and Slaugenhaupt, S.A. (2003) Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. Am. J. Hum. Genet., 72, 749-758.
24. Heemskerk, J., Tobin, A.J. and Bain, L.J. (2002) Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA. Trends Neurosci., 25, 494-496.
25. Lambert, J., Naeyaert, J.M., Callens, T., De Paepe, A. and Messiaen, L. (1998) Human myosin V gene produces different transcripts in a cell type-specific manner. Biochem. Biophys. Res. Commun., 252, 329-333.
26. Frischmeyer, P.A. and Dietz, H.C. (1999) Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet., 8, 1893-1900.
27. Noensie, E.N. and Dietz, H.C. (2001) A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat. Biotechnol., 19, 434-439.
28. Moller, L.B., Tumer, Z., Lund, C., Petersen, C., Cole, T., Hanusch, R., Seidel, J., Jensen, L.R. and Horn, N. (2000) Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. Am. J. Hum. Genet., 66, 1211-1220.
29. Kearney, J.A., Buchner, D.A., De Haan, G., Adamska, M., Levin, S.I., Foray, A.R., Albin, R.L., Jones, J.M., Montal, M., Stevens, M.J. et al. (2002) Molecular and pathological effects of a modifier gene on deficiency of the sodium channel Scn8a (Na(v)1.6). Hum. Mol. Genet., 11, 2765-2775.
30. Buchner, D.A., Trudeau, M. and Meisler, M.H. (2003) SCNM1, a putative RNA splicing factor that modifies disease severity in mice. Science, 301, 967-969.
31. Caceres, J.F., Stamm, S., Helfman, D.M. and Krainer, A.R. (1994) Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science, 265, 1706-1709.
32. Yang, X., Bani, M.R., Lu, S.J., Rowan, S., Ben-David, Y. and Chabot, B. (1994) The A1 and A1B proteins of heterogeneous nuclear ribonucleoparticles modulate 5′ splice site selection in vivo. Proc. Natl Acad. Sci. USA, 91, 6924-6928.
33. Anderson, S.L., Qiu, J. and Rubin, B.Y. (2003) EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem. Biophys. Res. Commun., 310, 627-633.
34. Fujimoto, N., Sueoka, N., Sueoka, E., Okabe, S., Suganuma, M., Harada, M. and Fujiki, H. (2002) Lung cancer prevention with (-)-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1. Int. J. Oncol., 20, 1233-1239.
35. Rattan, S.I. and Clark, B.F. (1994) Kinetin delays the onset of ageing characteristics in human fibroblasts. Biochem. Biophys. Res. Commun., 201, 665-672.
36. Olsen, A., Siboska, G.E., Clark, B.F. and Rattan, S.I. (1999) N(6)-Furfuryladenine, kinetin, protects against Fenton reaction-mediated oxidative damage to DNA. Biochem. Biophys. Res. Commun., 265, 499-502.
37. Blumenfeld, A., Slaugenhaupt, S.A., Liebert, C.B., Temper, V., Maayan, C., Gill, S., Lucente, D.E., Idelson, M., MacCormack, K., Monahan, M.A. et al. (1999) Precise genetic mapping and haplotype analysis of the familial dysautonomia gene on human chromosome 9q31. Am. J. Hum. Genet., 64, 1110-1118.